Skip to main content
Log in

The Taxoids

Comparative Clinical Pharmacology and Therapeutic Potential

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Paclitaxel and docetaxel are 2 compounds from the new taxoid class of anti-cancer agents. Both drugs are very similar in preclinical activity, mechanism of action and spectrum of clinical activity. Some subtle differences in the intracellular retention of docetaxel may account for its lack of schedule-related myelosuppression and greater potency, and may be relevant to the skin toxicity and oedema which it produces. Early data suggest that there may be differing behaviour of anthracycline/taxoid combinations with respect to cardiotoxicity.

Paclitaxel has been studied in several first-line combination therapy trials in ovarian cancer. Here, paclitaxel in combination with a platinum compound seems to have proven itself as a standard regimen. It is uncertain if docetaxel will be evaluated in this context.

An abundance of clinical data is available for both analogues in the advanced, metastatic setting of breast cancer. Both also have been compared as single agents with doxorubicin with the results suggesting paclitaxel in a 3-hour infusion is inferior to the anthracycline (in terms of response rate), and those of docetaxel suggesting it is superior to the same dose of doxorubicin. This indirect comparison favours the activity of docetaxel; however, it is clear that in the dose/schedules studied, the taxoid compounds are not equitoxic. Either agent by itself, in the treatment of metastatic breast cancer, remains appropriate; however, lack of cumulative toxicity may make paclitaxel more attractive in some situations where prolonged administration is foreseen.

Lung cancer trials have also confirmed the activity of both agents, although docetaxel appears to have slightly more promising activity in previously treated patients than paclitaxel. Paclitaxel in combination with cisplatin has been evaluated in randomised trials as first-line treatment of non-small-cell lung cancer (NSCLC). The results of these trials taken together suggest that this combination has an impact on survival similar to other new regimens now considered ‘standard’ in the front-line setting in this disease.

Unfortunately, despite all the phase II data generated in numerous tumour types, little else can be said about the role of either taxoid in the ‘standard’ management of malignant disease. It will be some years yet before taxoid-based combinations have been evaluated sufficiently in randomised trials such that the impact of this novel class can be adequately assessed in terms of survival and cure rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumour agents. VI: The isolation and structure of taxol: a novel antileukemic and antitumour agents from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–7

    Article  PubMed  CAS  Google Scholar 

  2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–7

    Article  PubMed  CAS  Google Scholar 

  3. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288–91

    Article  PubMed  CAS  Google Scholar 

  4. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747–55

    Article  PubMed  CAS  Google Scholar 

  5. Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3-nm resolution: the change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994; 269: 31785–92

    PubMed  CAS  Google Scholar 

  6. Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line [abstract]. Proc Am Assoc Cancer Res 1994; 35: 385

    Google Scholar 

  7. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22 Suppl. 4: 3–16

    CAS  Google Scholar 

  8. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs 1992; 3: 311–21

    Article  PubMed  CAS  Google Scholar 

  9. Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171–7

    PubMed  CAS  Google Scholar 

  10. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609–4

    PubMed  CAS  Google Scholar 

  11. Kris MG, O’Connel JP, Gralla R, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605–7

    PubMed  CAS  Google Scholar 

  12. Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7

    PubMed  CAS  Google Scholar 

  13. Wiernik PH, Schwartz EL, Straumann JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–93

    PubMed  CAS  Google Scholar 

  14. Ohnuma T, Zimet AS, Coffey VA, et al. Phase I study of taxol in a 24-hour infusion schedule [abstract]. Proc Am Assoc Cancer Res 1985; 26: 662

    Google Scholar 

  15. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232–9

    PubMed  CAS  Google Scholar 

  16. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–70

    PubMed  CAS  Google Scholar 

  17. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10: 275–8

    Article  PubMed  CAS  Google Scholar 

  18. Legha SS, Tenny DM, Krakow IR. Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4: 762–6

    PubMed  CAS  Google Scholar 

  19. Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179–84

    PubMed  CAS  Google Scholar 

  20. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621–9

    PubMed  CAS  Google Scholar 

  21. Eisenhauer EA, ten Bokkel-Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–66

    PubMed  CAS  Google Scholar 

  22. Tange UB, Lund B, Hansen HH, et al. Phase I study of Taxotere (docetaxel) in patients (pts) with solid tumors [abstract]. Proc Am Soc Clin Oncol 1994; 13: 406

    Google Scholar 

  23. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037–42

    PubMed  CAS  Google Scholar 

  24. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as an intravenous 1-hour infusion on a weekly basis. J Clin Oncol 1994; 12: 1458–67

    PubMed  CAS  Google Scholar 

  25. Burris HA, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour infusion. J Clin Oncol 1993; 11: 950–8

    PubMed  CAS  Google Scholar 

  26. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere, five day schedule. J Natl Cancer Inst 1992; 84: 1781–8

    Article  PubMed  CAS  Google Scholar 

  27. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523–7

    PubMed  CAS  Google Scholar 

  28. Piccart MJ, Klijn J, Paridaens R, et al. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC Investigational Drug Branch for Breast Cancer (IDBBC) [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75

    Article  Google Scholar 

  29. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688–99

    PubMed  CAS  Google Scholar 

  30. Postma TJ, Vermorken JB, Liefting AJM, et al. Paclitaxel induced neuropathy. Ann Oncol 1995; 6: 489–94

    PubMed  CAS  Google Scholar 

  31. Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–8

    Article  PubMed  CAS  Google Scholar 

  32. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004–14

    Article  PubMed  CAS  Google Scholar 

  33. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381–404

    Article  PubMed  CAS  Google Scholar 

  34. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127–35

    PubMed  CAS  Google Scholar 

  35. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532–8

    PubMed  CAS  Google Scholar 

  36. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180–90

    PubMed  CAS  Google Scholar 

  37. Longnecker S, Ross D, Grochow L. High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–9

    PubMed  CAS  Google Scholar 

  38. Lustig V, Rosing H, van Warmerdam LJC, et al. Limited sampling models for the pharmacokinetics of docetaxel. Clin Drug Treat 1997; 13: 247–54

    CAS  Google Scholar 

  39. Huizing MT, van Warmerdam LJC, Rosing H, et al. Limited sampling strategies for investigating paclitaxel pharmacokinetics in patients receiving 175 mg/m2 as a 3-hour infusion. Clin Drug Invest 1995; 9: 344–53

    Article  Google Scholar 

  40. Bruno R, Vivien N, Vergniol JC, et al. A population pharmacokinetics model for docetaxel (Taxotere®): model building and validation. J Pharmacokinet Biopharm 1996; 2: 153–73

    Google Scholar 

  41. Walle T, Walle UK, Kumar GN, et al. Taxol metabolism and disposition in cancer patients. Drug Metab Disp 1995; 23: 506–12

    CAS  Google Scholar 

  42. Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP56976 in a new ethanol-free formulation of Taxotere [abstract]. Ann Oncol 1992; 3 Suppl. 5: 53

    Google Scholar 

  43. Paccaly D, Sanderink G, Paccaly-Moulin A, et al. Docetaxel (RP 56976, Taxotere®) human pharmacokinetics: technical summary. Rhone-Poulenc Rorer, 1994 Jul. (Data on file)

  44. Huizing MT, Giaccone G, van Warmerdan LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317–29

    PubMed  CAS  Google Scholar 

  45. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Center (ECC) trial. Ann Oncol 1995; 6: 699–704

    PubMed  CAS  Google Scholar 

  46. Nannan Panday VR, Huizing MT, Willemse PHB, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24 Suppl. 11: S11–34–38

    Google Scholar 

  47. Venook AP, Egorin M, Brown JD, et al. Paclitaxel (Taxol) in patients with liver dysfunction (CALGB 9264) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 139

    Google Scholar 

  48. Huizing MT, Rosing H, Vermorken JB, et al. Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S192

    Article  Google Scholar 

  49. Bruno R, Hille D, Thomas L, et al. Population pharmacokinetics/pharmacodynamics of docetaxel (Taxotere®) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 457

    Google Scholar 

  50. Fulton B, Spencer CM. Docetaxel: a review of the pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51(6): 1075–92

    Article  PubMed  CAS  Google Scholar 

  51. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1691–703

    Google Scholar 

  52. Kennedy MJ, Zahurak ML, Donehower RC, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating factor in women with previously untreated breast cancer. J Clin Oncol 1996; 14: 783–91

    PubMed  CAS  Google Scholar 

  53. Holmes FA, Valero V, Walters RS, et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161–9

    PubMed  Google Scholar 

  54. Sledge Jr GW. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22: 123–5

    PubMed  CAS  Google Scholar 

  55. Holmes FA, Newman EA, Madden T, et al. Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer [abstract]. Ann Oncol 1994; 5: 191

    Google Scholar 

  56. Gianni L, Vigano L, Locarelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906–15

    PubMed  CAS  Google Scholar 

  57. Pronk LC, Schellens JHM, Planting AST, et al. Phase I and pharmacokinetic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071–9

    PubMed  CAS  Google Scholar 

  58. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132

    Google Scholar 

  59. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–805

    Article  PubMed  CAS  Google Scholar 

  60. Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–51

    PubMed  CAS  Google Scholar 

  61. Swain SM, Honig SF, Tefft MC, et al. A phase II trial of paclitaxel (Taxol®) as first-line treatment in advanced breast cancer. Invest New Drugs 1995; 13: 217–2

    Article  PubMed  CAS  Google Scholar 

  62. Davidson NG, Perren TJ, Chao YTS, et al. A phase II non-randomized study of paclitaxel (P) 225 mg/m2 over 3 hours q 21 days in patients (pts) failing initial therapy for breast cancer [abstract]. Proceedings of the Sixth International Congress on Anti-Cancer Treatment 1995; 5: 119

    Google Scholar 

  63. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169–75

    Article  PubMed  CAS  Google Scholar 

  64. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575–81

    PubMed  CAS  Google Scholar 

  65. Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996; 32A: 47–51

    Article  PubMed  CAS  Google Scholar 

  66. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858–67

    PubMed  CAS  Google Scholar 

  67. Peretz T, Sulkes A, Chollet P, et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC) [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75

    Article  Google Scholar 

  68. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152–9

    PubMed  CAS  Google Scholar 

  69. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877–84

    PubMed  CAS  Google Scholar 

  70. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 1995; 13: 2056–65

    PubMed  CAS  Google Scholar 

  71. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58–65

    PubMed  CAS  Google Scholar 

  72. Trudeau ME, Eisenhauer EA, Higgins BP Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422–8

    PubMed  CAS  Google Scholar 

  73. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314–22

    PubMed  CAS  Google Scholar 

  74. Dieras V, Fumoleau P, Chevallier B et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first-line chemotherapy (CT) in advanced breast cancer (ABC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 78

    Google Scholar 

  75. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the safety and efficacy of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996; 7: 165–71

    Article  PubMed  CAS  Google Scholar 

  76. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527–32

    PubMed  Google Scholar 

  77. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210–6

    Article  PubMed  CAS  Google Scholar 

  78. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel (Taxotere®): a highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886–94

    PubMed  CAS  Google Scholar 

  79. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879–85

    PubMed  CAS  Google Scholar 

  80. Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75

    Article  Google Scholar 

  81. Paridaens R, Bruning P, Klijn J, et al. An EORTC crossover trial comparing Taxol (T) and doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154a

    Google Scholar 

  82. Chan S, Friedrichs K, Noel D, et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154a

    Google Scholar 

  83. Fisherman JS, Cowan KH, Noone M, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-colony stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 774–82

    PubMed  CAS  Google Scholar 

  84. Gelmon KA, O’Reilly SE, Tolcher AW, et al. Phase I/II trial of bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185–91

    PubMed  CAS  Google Scholar 

  85. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687–93

    Article  PubMed  CAS  Google Scholar 

  86. Conte PF, Baldini E, Gennari A, et al. Dose-finding study and phannacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510–7

    PubMed  CAS  Google Scholar 

  87. Bourgeois H, Gruia G, Dieras V, et al. Docetaxel in combination with doxorubicin as first-line chemotherapy of metastatic breast cancer: a phase I dose-finding study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 148

    Google Scholar 

  88. Sledge Jr GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1a

    Google Scholar 

  89. Bishop JF, Dewar J, Tattersall MHN, et al. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 153a

    Google Scholar 

  90. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9

    PubMed  CAS  Google Scholar 

  91. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–53

    PubMed  CAS  Google Scholar 

  92. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive for ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748–53

    PubMed  CAS  Google Scholar 

  93. Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666–70

    PubMed  CAS  Google Scholar 

  94. Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016–9

    Article  PubMed  CAS  Google Scholar 

  95. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  96. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C, and Scottish Intergroup experience [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a

    Google Scholar 

  97. Muggia FM, Braly PS, Brady MF, et al. Phase III study of cisplatin (P) or paclitaxel (T) versus their combination in sub-optimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132 [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a

    Google Scholar 

  98. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895–902

    PubMed  CAS  Google Scholar 

  99. Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1995; 22 (6 Suppl. 14): 32–4

    PubMed  CAS  Google Scholar 

  100. ten Bokkel Huinink W, Veenhof, Heimerhorst T, et al. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1995; 22 (3 Suppl. 6): 97–100

    Google Scholar 

  101. Giaccone G, Huizing M, ten Bokkel Huinink W, et al. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers. Semin Oncol 1994; 21 (5 Suppl. 8): 34–8

    PubMed  CAS  Google Scholar 

  102. Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22 (5 Suppl. 12): 91–8

    PubMed  CAS  Google Scholar 

  103. Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a

    Google Scholar 

  104. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13: 2961–7

    Google Scholar 

  105. Vermorken JB, Huijskes R, Hoekman K, et al. Feasibility and efficacy of a 2-weekly taxol, epirubicin and cisplatin (TEC) regimen in patients with advanced ovarian cancer (ADOVCA) [abstract]. Proc Am Assoc Cancer Res 1996; 37: 169

    Google Scholar 

  106. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J Clin Oncol 1994; 12: 2301–8

    PubMed  CAS  Google Scholar 

  107. Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676–81

    Article  PubMed  CAS  Google Scholar 

  108. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388–94

    Article  PubMed  CAS  Google Scholar 

  109. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384–8

    Article  PubMed  CAS  Google Scholar 

  110. Gatzmeier U, Heckmayr M, Neuhauss R, et al. Phase II study of paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 1995; 12 Suppl. 2: S101–6

    Article  Google Scholar 

  111. Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996; 2: 941–5

    PubMed  CAS  Google Scholar 

  112. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1996; 14: 142–8

    PubMed  CAS  Google Scholar 

  113. Murphy WK, Winn RJ, Huber M, et al. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 363

    Google Scholar 

  114. Ruckdeschel J, Wagner Jr H, Williams C, et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of Taxol [abstract]. Proc Am Soc Clin Oncol 1994; 13: 357

    Google Scholar 

  115. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12: 1238–44

    PubMed  CAS  Google Scholar 

  116. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 1232–7

    PubMed  CAS  Google Scholar 

  117. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere®) is active in non-small cell lung cancer: a phase II study of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384–7

    Article  PubMed  CAS  Google Scholar 

  118. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: 335

    Google Scholar 

  119. Miller VA, Rigas JR, Francis PA, et al. Phase II trial of 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968–72

    Article  PubMed  CAS  Google Scholar 

  120. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative group study. J Clin Oncol 1996; 14: 1649–55

    PubMed  CAS  Google Scholar 

  121. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645–51

    PubMed  CAS  Google Scholar 

  122. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II toxicity, response and survival analysis. J Clin Oncol 1995; 13: 1860–70

    PubMed  CAS  Google Scholar 

  123. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer — a phase II trial. J Clin Oncol 1996; 14: 2054–60

    PubMed  CAS  Google Scholar 

  124. Shepherd FA, Latreille J, Crump M, et al, A phase I study of paclitaxel and ifosfamide in advanced non-small cell lung cancer. Ann Oncol 1996; 7: 311–3

    Article  PubMed  CAS  Google Scholar 

  125. Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23 (2 Suppl. 5): 19–21

    PubMed  CAS  Google Scholar 

  126. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 2682–6

    PubMed  CAS  Google Scholar 

  127. Kirkbride P, Eisenhauer E, Gelmon K, et al. Phase I trial of paclitaxel (Tax) and radical radiotherapy (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 392

    Google Scholar 

  128. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial [abstract]. Proc Am Soc Clin Oncol 1996; 15: 382

    Google Scholar 

  129. Giaccone G, Postmus P, Debruyne C, et al. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 1997; 16: 460a

    Google Scholar 

  130. LeChevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 350

    Google Scholar 

  131. Cole JT, Gralla RJ, Marques CB, et al. Phase I–II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 357

    Google Scholar 

  132. Kourousis C, Kakolyris S, Androullakis N, et al. First-line treatment on non-small cell lung carcinoma with docetaxel and vinorelbine: a phase II study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 405

    Google Scholar 

  133. Masters GA, Haraf DJ, Hoffman PC, et al. Phase I study of concomitant docetaxel (Taxotere, TXT) and radiation (RT) in advanced chest malignancies [abstract]. Proc Am Soc Clin Oncol 1996; 15: 374

    Google Scholar 

  134. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995; 13: 1430–5

    PubMed  CAS  Google Scholar 

  135. Kirschling RJ, Jung SH, Jett JR. A phase II study of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer (SCC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 326

    Google Scholar 

  136. Smit EF, Kloosterziel C, Groen HJM, et al. A phase II study of paclitaxel (P) in heavily pretreated patients with small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 394

    Google Scholar 

  137. Latreille J, Cormier Y, Martins H, et al. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 1996; 13: 343–5

    Article  PubMed  CAS  Google Scholar 

  138. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058–60

    Article  PubMed  CAS  Google Scholar 

  139. Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. Ann Oncol 1995; 5 Suppl. 6: S51–4

    Google Scholar 

  140. Thornton D, Singh K, Putz B, et al. A phase II trial of taxol in squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1994; 13: 288

    Google Scholar 

  141. Gebbia V, Testa A, Cannata G, et al. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996; 32A: 901–2

    Article  PubMed  CAS  Google Scholar 

  142. Catimel G, Verweij J, Mattijson V, et al. Docetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533–7

    PubMed  CAS  Google Scholar 

  143. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672–8

    PubMed  CAS  Google Scholar 

  144. Couteau C, Leyvraz S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 315

    Google Scholar 

  145. Ebihara S, Fujii M, Sasaki Y, et al. A late phase II study of docetaxel (Taxotere®) in patients with head and neck cancer (HNC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 399a

    Google Scholar 

  146. Vermorken JB, Catimel G, Stupp R, et al. Randomized phase II trial of methotrexate (MTX) versus two schedules of Taxol (T) in patients with advanced squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1997; 16: 410a

    Google Scholar 

  147. Fujii H, Sasaki Y, Ebihara S, et al. An early phase II study of docetaxel (Taxotere®) in patients with head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 14: 298

    Google Scholar 

  148. Jekunen AP, Christen RD, Shalinsky DR, et al. Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299–306

    Article  PubMed  CAS  Google Scholar 

  149. Forastiere AA, Leong T, Murphy B, et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 384a

    Google Scholar 

  150. Hitt R, Hornedo J, Colomer R, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol 1995; 22 Suppl. 15: 50–4

    PubMed  CAS  Google Scholar 

  151. Schoffski P, Wanders J, Catimel G, et al. Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 310

    Google Scholar 

  152. Posner M, Norris C, Colevas A, et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 387a

    Google Scholar 

  153. Bruntsch U, Heinrich B, Kaye SB, et al. Docetaxel (Taxotere) in advanced renal cell cancer: a phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1064–7

    Article  PubMed  CAS  Google Scholar 

  154. Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185–7

    PubMed  CAS  Google Scholar 

  155. Pazdur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (Taxotere®) in metastatic colorectal cancer. Ann Oncol 1994; 5: 468–70

    PubMed  CAS  Google Scholar 

  156. Sternberg CN, ten Bokkel Huinink WW, Smyth JF, et al. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group study. Br J Cancer 1994; 70: 376–9

    Article  PubMed  CAS  Google Scholar 

  157. Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478–81

    Article  PubMed  CAS  Google Scholar 

  158. Einzig A, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59–64

    Article  PubMed  CAS  Google Scholar 

  159. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895–9

    PubMed  CAS  Google Scholar 

  160. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1061–4

    Article  PubMed  CAS  Google Scholar 

  161. Einzig AI, Schuchter LM, Wadler S, et al. Phase II trial of Taxotere (RP 56976) in patients (pts) with metastatic melanoma previously untreated with cytotoxic chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 395

    Google Scholar 

  162. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792–5

    PubMed  CAS  Google Scholar 

  163. Kudelka AP, Winn R, Edwards CL, et al. Advanced squamous cell cancer (SCC) of the cervix: a multicenter phase II study of paclitaxel (Taxol) 250 mg/m2 administered intravenously (IV) over 3h every 21 days with G-CSF support [abstract]. Proc Am Soc Clin Oncol 1996; 15: 281

    Google Scholar 

  164. Kudelka AP, Verschraegen CF, Levy T, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anti Cancer Drugs 1996; 7: 398–401

    Article  PubMed  CAS  Google Scholar 

  165. Prados MD, Schold SC, Spence AM, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996; 14: 2316–21

    PubMed  CAS  Google Scholar 

  166. Chamberlain MC, Kormanink P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13: 2066–71

    PubMed  CAS  Google Scholar 

  167. Forsyth P, Cairncross G, Stewart D, et al. Phase II trial of docetaxel in patients with recurrent malignant glioma. Invest New Drugs 1996; 14: 203–6

    Article  PubMed  CAS  Google Scholar 

  168. Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent irradiation in adults with astrocytomas. J Clin Oncol 1996; 14: 600–9

    PubMed  CAS  Google Scholar 

  169. van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere™) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539–42

    PubMed  Google Scholar 

  170. Blackstein M, Eisenhauer EA, Bramwell V, et al. Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): a Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S177

    Article  Google Scholar 

  171. Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (STS) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 526

    Google Scholar 

  172. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086–91

    Article  PubMed  CAS  Google Scholar 

  173. Einzig AV, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Invest New Drugs 1995; 13: 223–7

    Article  PubMed  CAS  Google Scholar 

  174. Einzig AI, Lipsitz S, Wiernik PJ, et al. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) previously untreated with cytotoxic chemotherapy; the Easter Cooperative Oncology Group (ECOG) results [abstract]. Proc Am Soc Clin Oncol 1995; 14: 191

    Google Scholar 

  175. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380–3

    Article  PubMed  CAS  Google Scholar 

  176. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma or the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12: 2264–70

    PubMed  CAS  Google Scholar 

  177. Dreicer R, Gustin D, See WA, et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy [abstract]. Proc Am Soc Clin Oncol 1996: 15: 242

    Google Scholar 

  178. McCaffrey J, Hilton S, Bajorin D, et al. Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin based chemotherapy [abstract]. Proc Am Soc Clin Oncol 1995: 14: 233

    Google Scholar 

  179. Christou A, Roth B, Fox S, et al. Phase II trial of paclitaxel in refractory germ cell neoplasms [abstract]. Proc Am Soc Clin Oncol 1996; 15: 249

    Google Scholar 

  180. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31–4

    Article  PubMed  CAS  Google Scholar 

  181. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277–83

    PubMed  CAS  Google Scholar 

  182. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22: 67–75

    PubMed  CAS  Google Scholar 

  183. Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 1996; 19: 290–1

    Article  PubMed  CAS  Google Scholar 

  184. Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 381–6

    PubMed  CAS  Google Scholar 

  185. Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 583–7

    PubMed  CAS  Google Scholar 

  186. Younes A, Ayoub J-P, Hagemeister FB, et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin’s lymphoma refractory to a 3-hour schedule. J Clin Oncol 1996; 14: 543–8

    PubMed  CAS  Google Scholar 

  187. Goss P, Stewart A, Couture F, et al. A phase II study of paclitaxel in patients with refractory lymphomas [abstract]. Proc Am Soc Clin Oncol 1996: 15: 419

    Google Scholar 

  188. Dimopoulos MA, Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (Taxol). Ann Oncol 1994; 5: 757–9

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elizabeth A. Eisenhauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenhauer, E.A., Vermorken, J.B. The Taxoids. Drugs 55, 5–30 (1998). https://doi.org/10.2165/00003495-199855010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855010-00002

Keywords

Navigation